Lazzarato David Angelo reported acquisition or exercise transactions in this Form 4 filing.
Canopy Growth Corp director David Angelo Lazzarato received an equity award of 162,485 Common Shares on June 17, 2026. The award was granted at no cash cost to him as a compensation-related grant, not an open-market purchase.
The grant was made in the form of restricted stock units that vest in four equal installments on June 26, 2026, September 28, 2026, December 29, 2026, and March 29, 2027. Following this grant, he directly holds 234,533 Common Shares.
BAYERN JOSEPH reported acquisition or exercise transactions in this Form 4 filing.
Canopy Growth Corp director Joseph Bayern received an equity award of 108,324 common shares on June 17, 2026. The shares were granted as restricted stock units, a form of stock-based compensation awarded at no cash cost to him.
These RSUs vest in four equal installments on June 26, 2026, September 28, 2026, December 29, 2026, and March 29, 2027, aligning incentives over time. Following this grant, Bayern directly holds 148,324 common shares.
Yanofsky Theresa reported acquisition or exercise transactions in this Form 4 filing.
Canopy Growth Corp director Theresa Yanofsky received an equity award of 108,324 common shares on June 17, 2026. The shares were granted at no cash cost as restricted stock units (RSUs) and will vest in four equal installments on June 26, 2026, September 28, 2026, December 29, 2026 and March 29, 2027. After this grant, Yanofsky directly holds 161,469 common shares, reflecting her ongoing equity stake in the company.
Canopy Growth Corp officer Stewart Thomas Carlton reported a mix of equity award grants and a small share sale. He received 379,018 Common Shares as restricted stock units granted on June 17, 2026, which vest in three equal installments on June 15, 2027, June 15, 2028, and June 15, 2029. He was also granted 463,347 stock options exercisable at $0.99 per share, vesting annually over three years from the same grant date and expiring on June 17, 2032. On the same day, he disposed of 9,285 Common Shares at an average price of $0.9741, with the footnotes stating this disposition was tied to tax obligations from earlier RSU vesting. After these transactions, he directly held 616,398 Common Shares and 463,347 stock options.
Canopy Growth Corp officer Christelle Gedeon reported equity compensation changes. On June 17, 2026, she received a grant of 484,122 stock options with an exercise price of $0.99 per share, vesting in three equal annual installments and expiring on June 17, 2032.
On the same date she acquired 396,012 common shares and sold 58,994 common shares at $0.9741 per share, with the disposition associated with tax obligations from RSU vesting. After these transactions she directly held 705,506 common shares. The transactions were not reported as made under a Rule 10b5-1 trading plan.
Canopy Growth Corp Chief Executive Officer Luc Mongeau reported a mix of equity compensation grants and a share disposition. He received 1,056,152 common shares in the form of restricted stock units (RSUs), which vest in three equal installments on June 15, 2027, June 15, 2028 and June 15, 2029. He was also granted stock options for 1,291,139 common shares with a conversion price of $0.99 per share, vesting in three equal annual installments on the first, second and third anniversaries of June 17, 2026 and expiring on June 17, 2032. On the same date, 135,231 common shares were disposed of at $0.9741 per share in connection with tax obligations arising from the vesting of RSUs granted on June 3, 2025. Following these transactions, Mongeau directly holds 1,723,913 common shares.
Canopy Growth Corporation reported fourth-quarter and full-year 2026 results showing modest revenue growth but ongoing losses. Net revenue reached about C$71.2 million in Q4 FY2026, up 10% from a year earlier, and C$284.6 million for FY2026, a 6% annual increase driven by 20% growth in Canadian adult-use cannabis and 18% growth in Canadian medical cannabis. International medical cannabis revenue grew 68% in Q4 but declined 7% for the year, while Storz & Bickel device revenue fell 14% both in the quarter and full year.
Reported gross margin compressed to 12% in Q4 and 24% for FY2026, though adjusted gross margin improved to 27% in Q4 after excluding acquisition-related inventory charges. The company posted a FY2026 net loss from continuing operations of C$262.9 million, about 49% narrower than FY2025, and an adjusted EBITDA loss of C$20.2 million. Free cash outflow improved significantly to C$69.1 million from C$176.6 million, and Canopy ended FY2026 with C$364.7 million in cash and a net cash position of C$131 million following a recapitalization. Management expects net revenue growth, better margins, lower operating costs and positive adjusted EBITDA in FY2027.
Canopy Growth Corporation filed a comprehensive annual report that restates multiple prior years and quarters after identifying non-cash technical errors in accounting for certain U.S.-dollar share‑settled warrants, which should have been recorded as liabilities and marked to fair value.
The company has restated its 2024 and 2025 audited financial statements and several 2023–2025 quarters, and previously issued reports should no longer be relied on. Management found a material weakness in internal control over financial reporting, leading to a conclusion that internal controls and disclosure controls were not effective as of March 31, 2026.
Canopy details a cannabis-focused, brand-led global strategy, significant exposure to the U.S. market through its equity-method investment in Canopy USA, and expanding international medical operations. To support liquidity and refinancing, it entered into a senior secured U.S.$162.1 million term loan, launched several at-the-market equity programs, and completed the acquisition of MTL Cannabis, paying cash and issuing shares.
Canopy Growth Corporation has adopted a new Advance Notice By-Law, labeled By-Law No. 2, which was approved by its Board of Directors on May 26, 2026. This bylaw sets a formal process for shareholders to nominate directors at annual or special meetings.
The bylaw, which is already effective, must be submitted to shareholders for confirmation at the next annual general meeting expected in September 2026. It imposes clear deadlines, ownership thresholds and detailed disclosure requirements for any nominating shareholder, while allowing the Board to waive requirements at its discretion.
Canopy Growth Corporation is restating multiple past financial statements after identifying a non-cash technical accounting error related to certain U.S. dollar–denominated share-settled warrants. Because these warrants should have been treated as liabilities rather than equity, prior audited annual financials for fiscal years ended March 31, 2024 and 2025, and several interim quarterly results, should no longer be relied upon, and the related audit reports are also affected.
The company plans to correct this by filing a comprehensive Form 10-K for the year ended March 31, 2026, including restated figures, on June 15, 2026. Management expects the impact to be limited to balance sheet reclassifications and fair value adjustments that are non-cash and non-operational, with no change to underlying business performance. However, management expects to report a material weakness in internal control over financial reporting and has applied for a management cease trade order affecting certain directors and officers until the refiling is complete.